Recognized as innovative biopharma developing
a potentially safer and superior anticoagulant for patients with
implanted cardiac devices and rare cardiovascular
conditions
PONTE
VEDRA, Fla., Nov. 19,
2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc.
(Nasdaq: CVKD), a late-stage biopharmaceutical company developing
tecarfarin, a new vitamin K antagonist (VKA) anticoagulant, has
been recognized as the 2024 "Anticoagulation Therapy Company of the
Year" by Pharma Tech Outlook, an industry publication
focused on breakthrough pharmaceutical technologies. The award
underscores Cadrenal's commitment to addressing the significant
unmet needs of patients with implanted left ventricular assist
devices (LVADs) and other rare cardiovascular conditions who
require chronic anticoagulation. Cadrenal aims to develop a better
VKA blood thinner for these warfarin-dependent patients.
In addition to receiving the award, Cadrenal was featured in the
current edition of Pharma Tech Outlook.
Entitled Pioneering Innovation in Anticoagulation for Rare
Cardiovascular Conditions, the article highlights
tecarfarin, Cadrenal's lead candidate that is being developed to
potentially overcome many of the challenges associated with
warfarin anticoagulation therapy including drug-drug interactions
and wide variability requiring frequent dosing changes. Unlike VKA
warfarin, tecarfarin uses a unique metabolic pathway that is less
affected by drug-drug interactions and kidney impairment. By
providing a stable, once-daily, and reversible therapeutic,
Cadrenal seeks to improve patient outcomes and ease the burden on
patients and healthcare providers who face the complex
anticoagulation management needs of this population.
"We are honored to receive this recognition from Pharma Tech
Outlook," said Quang X. Pham,
founder and CEO of Cadrenal Therapeutics. "Our goal is to provide a
safer and superior blood thinner option for patients who rely on
chronic anticoagulation but are underserved by current treatments.
Warfarin, the first VKA anticoagulant, was approved more than 70
years ago yet no significant advancements in oral VKA drugs have
occurred since then."
"Cadrenal Therapeutics has demonstrated a commitment to filling
a serious gap in anticoagulation therapy," said Lisa Winget, Managing Editor at Pharma Tech
Outlook. "We are pleased to recognize Cadrenal's innovative
approach to developing a new treatment to serve patients with LVADs
and other rare cardiovascular conditions."
With orphan drug and fast-track designations, tecarfarin is
uniquely positioned to fill the gap in chronic anticoagulation
treatment options for patients with LVADs and rare cardiovascular
conditions such as end-stage kidney disease (ESKD) with atrial
fibrillation.
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics is a late-stage biopharmaceutical company
developing tecarfarin, a new vitamin K antagonist (VKA) to provide
potentially safer and superior chronic anticoagulation for patients
with implanted cardiac devices or rare cardiovascular conditions.
Cadrenal is focused on evaluating tecarfarin versus warfarin in
reducing adverse events such as strokes, heart attacks, and bleeds
in these patients. With tecarfarin, Cadrenal aims to address many
of warfarin's challenges such as drug interactions, frequent dosing
adjustments, and kidney impairment effects, which are common in
these patients. Tecarfarin has an orphan drug designation for left
ventricular assist device (LVAD) patients and both orphan drug and
fast-track designations for end-stage kidney disease patients with
atrial fibrillation. Cadrenal is advancing a pivotal trial and
pursuing clinical and commercial partnerships, with plans to study
mechanical heart valve patients facing anticoagulation
difficulties. Visit www.cadrenal.com to learn more.
Safe Harbor
Any statements contained in this press release about future
expectations, plans, and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
"forward-looking statements." These statements include statements
regarding Cadrenal's anticoagulant being a potentially
safer and superior anticoagulant for patients with implanted
cardiac devices and rare cardiovascular conditions; Cadrenal
developing a better VKA blood thinner for warfarin-dependent
patients; Cadrenal's lead candidate potentially overcoming many of
the challenges associated with warfarin anticoagulation therapy
including drug-drug interactions and wide variability requiring
frequent dosing changes; Cadrenal improving patient outcomes and
easing the burden on patients and healthcare providers who face the
complex anticoagulation management needs of this population;
Cadrenal providing a safer and superior blood thinner option for
patients who rely on chronic anticoagulation but are underserved by
current treatments; and tecarfarin being uniquely positioned
to fill the gap in chronic anticoagulation treatment options for
patients with LVADs and rare cardiovascular conditions such as
end-stage kidney disease (ESKD) with atrial fibrillation; and
advancing a pivotal trial and pursuing clinical and commercial
partnerships, with plans to study mechanical heart valve patients
facing anticoagulation difficulties. The words "anticipate,"
"believe," "continue," "could," "estimate," "expect," "intend,"
"may," "plan," "potentially," "predict," "project," "should,"
"target," "will," "would" and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including the ability of tecarfarin to be a safer and
superior anticoagulant for patients with implanted cardiac devices
and rare cardiovascular conditions and being a better VKA
blood thinner for warfarin-dependent patients, the ability of the
Company to advance tecarfarin in a pivotal trial and to advance
tecarfarin with patients with LVADs and those with AFib and ESKD,
the ability to advance commercial partnerships and the other risk
factors described in the Company's Annual Report on Form 10-K for
the year ended December 31, 2023, and the Company's subsequent
filings with the Securities and Exchange Commission, including
subsequent periodic reports on Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K. Any forward-looking statements
contained in this press release speak only as of the date hereof
and, except as required by federal securities laws, the Company
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-named-anticoagulation-therapy-company-of-the-year-by-pharma-tech-outlook-302309432.html
SOURCE Cadrenal Therapeutics, Inc.
